Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $170.41 Average Price Target from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have been assigned an average recommendation of “Moderate Buy” from the twenty-three ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $168.55.

A number of research firms recently weighed in on SRPT. Cantor Fitzgerald restated an “overweight” rating and issued a $163.00 price target on shares of Sarepta Therapeutics in a report on Tuesday. Scotiabank initiated coverage on Sarepta Therapeutics in a report on Friday, March 7th. They set a “sector perform” rating and a $105.00 target price on the stock. StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft lowered their target price on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a report on Wednesday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $202.00 target price on shares of Sarepta Therapeutics in a report on Tuesday.

Sarepta Therapeutics Stock Performance

SRPT opened at $79.97 on Monday. The stock has a market cap of $7.76 billion, a P/E ratio of 63.98 and a beta of 0.79. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The stock’s 50 day simple moving average is $109.26 and its 200 day simple moving average is $118.86. Sarepta Therapeutics has a 1-year low of $73.06 and a 1-year high of $173.25.

Insider Buying and Selling

In related news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now directly owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Manchester Capital Management LLC raised its position in shares of Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after buying an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB raised its position in shares of Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after buying an additional 156 shares during the period. Sunbelt Securities Inc. raised its position in shares of Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after buying an additional 232 shares during the period. Huntington National Bank raised its position in shares of Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after buying an additional 175 shares during the period. Finally, Newbridge Financial Services Group Inc. purchased a new position in shares of Sarepta Therapeutics in the 4th quarter worth $36,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.